ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
EMERYVILLE, Calif., Nov. 01, 2016 -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas, will present at the Stifel 2016 Healthcare Conference in New York on Tuesday, November 15th 2016 at 9:30 a.m. Eastern Time.
The presentation will be webcast live from the investor relations section of the Adamas website at http://ir.adamaspharma.com/events.cfm and available for approximately two weeks.
About Adamas Pharmaceuticals, Inc.
Adamas is a pharmaceutical company that is developing new medicines to improve the daily lives of those affected by chronic neurologic disorders, including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis and epilepsy. Adamas has pioneered a platform based on an understanding of time-dependent biologic effects of disease activity and drug response to potentially achieve symptomatic relief without additional tolerability issues. We have developed a portfolio of Chrono-Synchronous Therapies (CSTs) to address chronic neurologic disorders. In addition to ADS-5102, we are investigating ADS-4101 for the improved control of epileptic seizures. Additionally through our license agreement with Forest Laboratories Holding Ltd. (a wholly owned subsidiary of Allergan plc), we are eligible to receive royalties on sales of NAMENDA XR® and NAMZARIC® beginning in June of 2018 and May of 2020, respectively. For more information, please visit www.adamaspharma.com.
NAMENDA XR® and NAMZARIC® are registered trademarks of Merz Pharma GmbH & Co. KGaA.
Contact: Martin Forrest VP Corporate Communications and Investor Relations 510-450-3528
